P-tau

P-tau

, p-Tau (pē′tow′)
Tau protein that is abnormally phosphorylated. Its concentrated presence in the cerebrospinal fluid is indicative of Alzheimer disease.
References in periodicals archive ?
20],[21] Although the role of p-tau in AD pathology is thought to be secondary to A[sz] accumulation in the brain, a growing body of evidence suggests that tau has unique roles in AD that are A[sz] independent.
El estudio microscopico de la enfermedad se basa en la busqueda de depositos de la proteina p-tau como ovillo neurofibrilares e hilos neurofibrilares en la corteza cerebral que generalmente se encuentra en torno a pequenos vasos sanguineos en el fondo de los surcos (7).
In recent years, there have been many domestic and foreign studies on the biological markers of cerebrospinal fluid in the patients with AD, and high levels of the T-tau, P-tau found in cerebrospinal fluid (CSF) is at this point an indisputable fact.
Erik Portelius: There is variability in the measurements of A[beta]-42, t-tau, and p-tau between clinical centers and laboratories.
The researchers found that people who have higher pulse pressure are more likely to have the Alzheimer's biomarkers amyloid-beta, or plaques, and p-tau protein, or tangles, in their cerebral spinal fluid than those with lower pulse pressure.
Kester and her colleagues explored the relationship between small-vessel disease pathology and AD pathology by assessing MRI images of microbleeds, white-matter hyperintensities, and lacunes and correlating these with CSF (cerebrospinal fluid) levels of beta-amyloid 42, total tau, and p-tau.
The study found that people who have higher pulse pressure are more likely to have the Alzheimer's biomarkers amyloid beta, or plaques, and p-tau protein, or tangles, in their cerebral spinal fluid than those with lower pulse pressure.
Their models produce cognitive impairment, as assessed in the Morris Water Maze, and increase expression of tau, p-tau, APP, A[sz] and alpha-synuclein in the brain.
The researchers also found that the patients who developed AD within five years of the baseline test also had reduced A[beta]42 levels, although they did not have significantly higher levels of T-tau and P-tau.
One study, published in the July 22 issue of the Journal of the American Medical Association, found that patients were more likely to develop AD if their cerebrospinal fluid (CSF) contained low levels of the protein beta-amyloid 42 (which is one of the main ingredients of the plaque associated with AD), and elevated levels of tau and a type of tau identified as P-tau (a source of the neurofibrillary tangles associated with AD).